<DOC>
	<DOCNO>NCT02384759</DOCNO>
	<brief_summary>This FFCD 11-01 - PRODIGE 25 trial proposes study , preliminary strategic study evaluate usefulness include targeted therapeutic first line aflibercept +/- LV5FU2 .</brief_summary>
	<brief_title>Aflibercept +/- LV5FU2 First Line Non-resectalbe Metastatic Colorectal Cancers</brief_title>
	<detailed_description>The aflibercept-5-FU combination never evaluate yet . Aflibercept , dose 4 mg/kg , already use combination 5-FU dos use simplify LV5FU2 regimen ( folinic acid 400 mg/m2 IV 90 min , 5-FU 400 mg/m2 IV bolus D1 , follow continuous perfusion 5-FU 2,400 mg/m2 46h ) ( 23 ) part above-mentioned VELOUR trial , evaluate combination FOLFIRI ( = simplify LV5FU2 + irinotecan ) . This trial precede phase I trial validate dos use ( 24 ) . It therefore necessary perform phase I trial use dose 5-FU without irinotecan , within context strategy reduce toxicity patient treat long period , search maximum tolerate dose combination . The aflibercept-LV5FU2 combination useful patient never resectable operable , 5-FU monotherapy suggest delay toxicity combine chemotherapy . Within context , possible aflibercept provide survival benefit . The previous VELOUR trial ( 18 ) indicate toxicity would major effect quality life increase hope prolonged progression-free survival arm aflibercept . This FFCD 11-01 - PRODIGE 25 trial proposes study , preliminary strategic study evaluate usefulness include targeted therapeutic first line . This trial evaluate efficacy combination tolerance study toxicity quality life . Quality life study via EORTC questionnaire QLQ-C30 . The thymidylate synthase polymorphism type 2R2R-2R3R versus 3R3R seem predict great efficacy 5-FU monotherapy . Stratification criterion confirm negate prognostic predictive nature 5-FU efficacy link polymorphism . The draft version trial study evaluate scientific council Fédération Francophone de Cancérologie Digestive ( FFCD ) Digestive Group Fédération Nationale de Centres de Lutte Contre le Cancer ( FNCLCC ) within framework Partnership Research Digestive Oncology ( PRODIGE cooperation ) .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>Age ≥ 65 year General condition WHO ≤ 2 Metastatic rectal colonic adenocarcinoma , histologically prove primary tumour metastasis Metastases nonresectable and/or patient inoperable patient single agent chemotherapy combine antiangiogenic agent appropriate approach At least one measurable target accord RECIST v1.1 criterion , previously irradiate No previous treatment metastatic disease . Previous chemotherapy adjuvant situation complete 6 month diagnosis metastasis authorize . Adequate biological examination : Hb &gt; = 9 g/dl , polynuclear neutrophils &gt; = 1,500/mm3 , platelet &gt; =100,000/mm3 , total bilirubin &lt; = 1.5 x UNL , creatinine clearance , calculate accord CockroftGault formula , &gt; 50 ml/min creatininemia &lt; 1.5 x UNL , ALP &lt; 5 x UNL , transaminases &lt; 5 x ULN , GGT &lt; 5 x UNL Proteinuria ( strip ) &lt; 2+ ; &gt; = 2+ , test proteinuria 24 hour must ≤ 1 g. Central genotyping thymidylate synthase ( TS ) blood DNA Patients treat anticoagulant ( coumadin , warfarin ) include INR closely monitor . A change anticoagulant treatment low molecular weight heparin preferable order respect indication Signed write informed consent obtain prior inclusion Patients primary tumour place present clinical symptom ( occlusion , haemorrhage ) History brain metastasis , uncontrolled spinal cord compression , carcinomatous meningitis new evidence brain leptomeningeal disease . Uncontrolled hypercalcemia Uncontrolled hypertension ( SBP &gt; 150 mmHg DBP &gt; 100 mmHg ) history hypertensive attack hypertensive encephalopathy Any progressive pathology balance past 6 month : hepatic insufficiency , renal insufficiency , respiratory insufficiency , Any follow within 6 month prior inclusion : myocardial infarction , severe/unstable angina pectoris , coronary/peripheral artery bypass graft , NYHA class III IV congestive heart failure , stroke transient ischemic attack . Any follow within 3 month prior inclusion : Grade 34 gastrointestinal bleeding/hemorrhage , treatment resistant peptic ulcer disease , erosive oesophagitis gastritis , infectious inflammatory bowel disease , diverticulitis , pulmonary embolism uncontrolled thromboembolic event , wound fracture bone Major surgery 28 day precede start treatment Known acquire immunodeficiency syndrome ( AIDSrelated illness ) know HIV disease require antiretroviral treatment . Treatment concomitant anticonvulsivant agent CYP3A4 inducer ( phenytoin , phenobarbital , carbamazepine ) , unless discontinue &gt; 7 day . Antitumoral treatment trial treatment ( chemotherapy , target therapy , immunotherapy ) Macronodular peritoneal carcinosis ( risk perforation ) Known DPD deficit Prior history malignant haemopathy cancer except treat 5 year ago consider cure , situ cervical carcinoma treat skin cancer ( exclude melanoma ) Patients new oral anticoagulant therapy ( rivaroxaban XARELTOR , apixaban ELIQUIS , dagigatran PRADAXA except relay vitamine K antagonist therapy ) Any contraindication treatment use trial Impossibility undergoing medical monitoring trial geographic , social psychological reason</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>cancer , colorectal ,</keyword>
</DOC>